The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA<sub>1c(v)</sub>-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al.

Stryker, Matthew D; Schulman-Marcus, Joshua; Sidhu, Mandeep S

The Antidiabetic Armamentarium: Reducing the Residual Cardiovascular Risk with HbA_1c(v)-Lowering Medications : Editorial to: "GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials" by Jia X, Alam M, Ye Y et al.

Stryker, Matthew D; Schulman-Marcus, Joshua; Sidhu, Mandeep S.

Afiliação

Stryker MD; Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, OB212G, Albany, NY, 12208, USA. matthew.stryker@acphs.edu.
Schulman-Marcus J; Division of Cardiology, Albany Medical Center, 47 New Scotland Avenue, Albany, NY, 12208, USA.
Sidhu MS; Division of Cardiology, Albany Medical Center, 47 New Scotland Avenue, Albany, NY, 12208, USA.

Cardiovasc Drugs Ther ; 32(1): 1-3, 2018 02.

Article em En | MEDLINE | ID: mdl-29455345

Assuntos

Doenças Cardiovasculares; Receptor do Peptídeo Semelhante ao Glucagon 1/agonistas; Humanos; Hipoglicemiantes; Liraglutida; Fatores de Risco

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares Tipo de estudo: Etiology_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google